AstraZeneca sues Ranbaxy over Nexium.
Economic Times (New Delhi, India), November, 2005
Nov. 23--DELHI -- Ranbaxy has another high profile legal battle coming up, with AstraZeneca on Tuesday saying that it was suing the Indian drug major for challenging the patent of the latter's blockbuster anti-ulcer drug, Nexium. The legal battle with AstraZeneca is set to take off even as Ranbaxy is fighting a similar patent challenge case with another MNC, Pfizer, over its cholesterol lowering drug Lipitor.
AstraZeneca had indicated last month itself that it was "evaluating" the options against Ranbaxy when the latter made the para IV ANDA filing for the generic version of Nexium. Nexium (esomeprazole) is AstraZeneca's best-selling drug and is the world's third largest-selling prescription drug, registering sales of about $3.9bn last year.
Reacting...
Most Recent Business Articles
- Multiple criteria evaluation and optimization of transportation systems
- Multi-criteria analysis procedure for sustainable mobility evaluation in urban areas
- A two-leveled multi-objective symbiotic evolutionary algorithm for the hub and spoke location problem
- Multi-criteria analysis for evaluating the impacts of intelligent speed adaptation
- The development of Taiwan arterial traffic-adaptive signal control system and its field test: a Taiwan experience
Most Recent Business Publications
Most Popular Business Articles
- 7 tips for effective listening: productive listening does not occur naturally. It requires hard work and practice - Back To Basics - effective listening is a crucial skill for internal auditors
- FAS 109: a primer for non-accountants - Financial Accounting Standards Board's "Statement 109: Accounting for Income Taxes"
- LIFO vs. FIFO: a return to the basics
- Design a commission plan that drives sales - Sales Commissions
- Too Young to Rent a Car? - 25-years-old the minimum age for car renting - Brief Article
